Advocacy intelligence hub — real-time data for patient organizations
Hangzhou Polymed Biopharmaceuticals, Inc. — PHASE1
National Cancer Institute (NCI) — PHASE1
Temodar: FDA approved
Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Acute myeloid leukemia with recurrent genetic anomaly news →
George Chen
Roswell Park Cancer Institute
Philip L. McCarthy, MD
Roswell Park Cancer Institute
Evan C Chen
Dana-Farber - Harvard Cancer Center LAO
Thomas J. Walsh, MD
National Cancer Institute (NCI)
Gregory Yanik, MD, MD
Children's Oncology Group
📍 ANN ARBOR, MI
Ann E. Woolfrey, MD, M.D
Fred Hutchinson Cancer Center
📍 SEATTLE, WA
View all Acute myeloid leukemia with recurrent genetic anomaly specialists →